Recent developments in liposomal drug delivery systems for the treatment of retinal diseases

Andrew J. Urquhart*, Anne Zebitz Eriksen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Diseases of the retina cause vision loss and blindness, which have a profound impact on an individual's quality of life. The number of therapies available to treat retinal diseases is limited. Nanoparticle (NP)-based medicines represent one strategy to expand both the number of available therapies and the range of retinal diseases treated. Liposomes, phospholipid vesicles that frequently contain cholesterol and/or modified surface chemistries, have already had minor success in retinal disease treatment and hold significant promise. Here, we provide a snapshot of recent research developments in liposomal drug delivery systems for retinal diseases and discuss the challenges associated with liposomal systems in the context of recent developments.
Original languageEnglish
JournalDrug Discovery Today
Volume24
Issue number8
Pages (from-to)1660-1668
ISSN1359-6446
DOIs
Publication statusPublished - 2019

Cite this

@article{5c1fb1494cef41e785e18a8fb65caf4b,
title = "Recent developments in liposomal drug delivery systems for the treatment of retinal diseases",
abstract = "Diseases of the retina cause vision loss and blindness, which have a profound impact on an individual's quality of life. The number of therapies available to treat retinal diseases is limited. Nanoparticle (NP)-based medicines represent one strategy to expand both the number of available therapies and the range of retinal diseases treated. Liposomes, phospholipid vesicles that frequently contain cholesterol and/or modified surface chemistries, have already had minor success in retinal disease treatment and hold significant promise. Here, we provide a snapshot of recent research developments in liposomal drug delivery systems for retinal diseases and discuss the challenges associated with liposomal systems in the context of recent developments.",
author = "Urquhart, {Andrew J.} and Eriksen, {Anne Zebitz}",
year = "2019",
doi = "10.1016/j.drudis.2019.04.004",
language = "English",
volume = "24",
pages = "1660--1668",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "8",

}

Recent developments in liposomal drug delivery systems for the treatment of retinal diseases. / Urquhart, Andrew J.; Eriksen, Anne Zebitz.

In: Drug Discovery Today, Vol. 24, No. 8, 2019, p. 1660-1668.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Recent developments in liposomal drug delivery systems for the treatment of retinal diseases

AU - Urquhart, Andrew J.

AU - Eriksen, Anne Zebitz

PY - 2019

Y1 - 2019

N2 - Diseases of the retina cause vision loss and blindness, which have a profound impact on an individual's quality of life. The number of therapies available to treat retinal diseases is limited. Nanoparticle (NP)-based medicines represent one strategy to expand both the number of available therapies and the range of retinal diseases treated. Liposomes, phospholipid vesicles that frequently contain cholesterol and/or modified surface chemistries, have already had minor success in retinal disease treatment and hold significant promise. Here, we provide a snapshot of recent research developments in liposomal drug delivery systems for retinal diseases and discuss the challenges associated with liposomal systems in the context of recent developments.

AB - Diseases of the retina cause vision loss and blindness, which have a profound impact on an individual's quality of life. The number of therapies available to treat retinal diseases is limited. Nanoparticle (NP)-based medicines represent one strategy to expand both the number of available therapies and the range of retinal diseases treated. Liposomes, phospholipid vesicles that frequently contain cholesterol and/or modified surface chemistries, have already had minor success in retinal disease treatment and hold significant promise. Here, we provide a snapshot of recent research developments in liposomal drug delivery systems for retinal diseases and discuss the challenges associated with liposomal systems in the context of recent developments.

U2 - 10.1016/j.drudis.2019.04.004

DO - 10.1016/j.drudis.2019.04.004

M3 - Journal article

VL - 24

SP - 1660

EP - 1668

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 8

ER -